Hoth Therapeutics wins US patent allowance for HT-KIT oncology platform

Hoth Therapeutics, Inc

Hoth Therapeutics, Inc

HOTH

0.00
  • Hoth Therapeutics received a USPTO notice of allowance for patent claims covering its HT-KIT antisense oncology platform.
  • Claims cover composition of matter, pharmaceutical compositions, methods targeting MS4A6A pre-mRNA splicing to reduce FcεRI surface expression.
  • Company framed the allowance as strengthening IP protection for HT-KIT, an orphan drug-designated mast cell disease program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260818PR_NEWS_USPR_____NY67301) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.